Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human lactoferrin + lysozyme oral solution
- Development stage
- Unknown
- Lead developer
- Wuhan Healthgen Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Recombinant human lactoferrin + lysozyme oral solution is a plant-derived biologic combination therapy developed by Wuhan Healthgen Biotechnology (also known as Wuhan Heyi Biotechnology). The drug consists of two active ingredients: recombinant human lactoferrin (OsrhLF) and recombinant human lysozyme (OsrhLYZ), both produced using a proprietary rice endosperm cell bioreactor platform. It is designed to provide antimicrobial and mucosal defense activity in the gastrointestinal tract, specifically targeting infectious diarrhea caused by rotavirus in children aged 6 months to 5 years. The drug is administered orally for five consecutive days and is currently in Phase 2 clinical development in China, where it is classified as a Class 1 biological innovative drug.
- Other names
- recombinant human lactoferrin + lysozyme oral solutionOsrhLF + OsrhLYZ oral solution重组人乳铁蛋白溶菌酶口服液
02
Targets
Fe³⁺ (Ferric ion)VP4/VP7 (Rotavirus attachment proteins (VP4 and VP7))PGN (Peptidoglycan)
Beyond the preview
Go deeper on recombinant human lactoferrin + lysozyme oral solution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human lactoferrin + lysozyme oral solution.